News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its Chief Executive Officer Damien McDonald will present a general business update during
Acadia Healthcare Set to Open Four New Comprehensive Treatment Centers
Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.
This press release features
Acadia Healthcare Acquires Four CTC Facilities in Georgia
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the recent acquisition of four comprehensive treatment centers (“CTC”) from Georgia-based Brand New Start Treatment Centers. The four
QIAGEN übertrifft Ausblick für Q3 2022 mit einem Umsatzwachstum von 18% (CER) beim Nicht-COVID-Portfolio und hebt Ausblick für das Gesamtjahr 2022 an
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ergebnisse für das dritte Quartal und die ersten neun Monate 2022 bekannt gegeben und die Prognose für das Gesamtjahr 2022
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter of 2022 and first nine months of 2022, and increased the outlook for full-year 2022.
Net sales for
Xencor Reports Third Quarter 2022 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its cell therapy contract development and manufacturing (CDMO) facility in Memphis, Tenn. The expanded
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on December 5, 2022
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Acadia Healthcare to Participate in Credit Suisse 31st Annual Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Credit Suisse 31st Annual Healthcare Conference, November 7 - 10, 2022, at Terranea Resort in
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Premier Inc. to Participate in Credit Suisse 31st Annual Healthcare Conference on November 8, 2022
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories Announces Third-Quarter 2022 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2022. For the quarter, revenue was $989.2 million, an increase of 10.4% from $895.9
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
LivaNova Reports Third-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022.
Financial Summary and Highlights1
Premier, Inc. Reports Fiscal Year 2023 First Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 first quarter ended September 30, 2022.
"Our
Chemed Reports Third-Quarter 2022 Results - Increases 2022 Earnings Guidance
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Chemed Corporation to Present at the 2022 Credit Suisse Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 31st Annual Credit Suisse Healthcare Conference on Wednesday, November 9, 2022, at approximately 2:00 p.m
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc